Title
Orthovoltage X-Rays Exhibit Increased Efficacy Compared with g-Rays in Preclinical Irradiation
Date Issued
01 August 2022
Access level
open access
Resource Type
journal article
Author(s)
Bell B.I.
Vercellino J.
Brodin N.P.
Velten C.
Nanduri L.S.Y.
Nagesh P.K.B.
Tanaka K.E.
Fang Y.
Wang Y.
English J.
Schumacher M.M.
Duddempudi P.K.
Asp P.
Koba W.
Shajahan S.
Liu L.
Tome W.A.
Yang W.L.
Kolesnick R.
Guha C.
Montefiore Medical Center
Publisher(s)
American Association for Cancer Research Inc.
Abstract
Radionuclide irradiators (137Cs and 60Co) are commonly used in preclinical studies ranging from cancer therapy to stem cell biology. Amidst concerns of radiological terrorism, there are institutional initiatives to replace radionuclide sources with lower energy X-ray sources. As researchers transition, questions remain regarding whether the biological effects of γ-rays may be recapitulated with orthovoltage X-rays because different energies may induce divergent biological effects. We therefore sought to compare the effects of orthovoltage X-rays with 1-mm Cu or Thoraeus filtration and 137Cs g-rays using mouse models of acute radiation syndrome. Following whole-body irradiation, 30-day overall survival was assessed, and the lethal dose to provoke 50% mortality within 30-days (LD50) was calculated by logistic regression. LD50 doses were 6.7 Gy, 7.4 Gy, and 8.1 Gy with 1-mm Cufiltered X-rays, Thoraeus-filtered X-rays, and 137Cs γ-rays, respectively. Comparison of bone marrow, spleen, and intestinal tissue from mice irradiated with equivalent doses indicated that injury was most severe with 1-mm Cu-filtered X-rays, which resulted in the greatest reduction in bone marrow cellularity, hematopoietic stem and progenitor populations, intestinal crypts, and OLFM4+intestinal stem cells. Thoraeus-filtered X-rays provoked an intermediate phenotype, with 137Cs showing the least damage. This study reveals a dichotomy between physical dose and biological effect as researchers transition to orthovoltage X-rays. With decreasing energy, there is increasing hematopoietic and intestinal injury, necessitating dose reduction to achieve comparable biological effects. 2022 American Association for Cancer Research.
Start page
2678
End page
2691
Volume
82
Issue
15
Language
English
OCDE Knowledge area
Radiología, Medicina nuclear, Imágenes médicas
Scopus EID
2-s2.0-85135431239
PubMed ID
Source
Cancer Research
ISSN of the container
0008-5472
Sponsor(s)
This work was supported by R01CA257509, R01CA226861, R01CA198095, U01DK103155, U01AI138324, U01AI133608, U01AI133598, and R01AG057429. The authors thank the Albert Einstein Cancer Center for their support (P30CA013330). They also thank the Albert Einstein College of Medicine Histology and Comparative Pathology Facility, Flow Cytometry Core Facility (1S10OD026833), and Analytical Imaging Facility (1S10OD019961) for their valuable assistance with this project.
This work was supported by R01CA257509, R01CA226861, R01CA198095, U01DK103155, U01AI138324, U01AI133608, U01AI133598, and R01AG057429. The authors thank the Albert Einstein Cancer Center for their support (P30CA013330). They also thank the Albert Einstein College of Medicine
J. Vercellino reports grants from NIH during the conduct of the study. L.S.Y. Nanduri reports grants from NIH during the conduct of the study. K.E. Tanaka reports grants from NIH during the conduct of the study. R. Macedo reports grants from NIH during the conduct of the study. P.K. Duddempudi reports grants from Albert Einstein College of Medicine during the conduct of the study. W. Koba reports grants from NIH during the conduct of the study. S. Shajahan reports grants from NIH during the conduct of the study. R. Kolesnick reports patents unrelated to this work (US7195775B1, US7850984B2, US10052387B2, US8562993B2, US9592238B2, US20150216971A1, US20170335014A1, US20170333413A1, US20180015183A1, US10414533B2, US10450385B2) and is a co-founder of Ceramedix Holding LLC. C. Guha reports grants from NIH during the conduct of the study; grants and personal fees from Janssen; grants from Celldex; and grants and personal fees from Varian outside the submitted work. No disclosures were reported by the other authors.
Sources of information:
Directorio de Producción Científica
Scopus